JP2019216716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019216716A5 JP2019216716A5 JP2019120643A JP2019120643A JP2019216716A5 JP 2019216716 A5 JP2019216716 A5 JP 2019216716A5 JP 2019120643 A JP2019120643 A JP 2019120643A JP 2019120643 A JP2019120643 A JP 2019120643A JP 2019216716 A5 JP2019216716 A5 JP 2019216716A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- biomarker
- cancer
- level
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000000090 biomarker Substances 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 4
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 4
- 238000001574 biopsy Methods 0.000 claims 3
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 229960003433 Thalidomide Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- ZXWQZGROTQMXME-KMPXOGLXSA-N 2-hydroxy-N-[(E)-3-hydroxy-1-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)\C=C\CCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-KMPXOGLXSA-N 0.000 claims 1
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 1
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 claims 1
- 208000002576 AIDS-related Kaposi sarcoma Diseases 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 210000000349 Chromosomes Anatomy 0.000 claims 1
- 229920002676 Complementary DNA Polymers 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000000952 Spleen Anatomy 0.000 claims 1
- 102100014283 ZFP91 Human genes 0.000 claims 1
- 101700070870 ZFP91 Proteins 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Claims (27)
- 化合物が抗腫瘍剤として有効であるかどうかを決定する方法であって:
(a)第1の細胞を該化合物と接触させること;
ここで、任意に、該細胞は癌細胞であるか、又は任意に、該細胞は免疫細胞であり;
(b)工程(a)の該第1の細胞から第1の試料を得ること、
(c)該第1の試料中のバイオマーカーのレベルを決定すること;及び
(d)工程(c)の該バイオマーカーのレベルを参照試料中のバイオマーカーのレベルと比較することを含み、ここで、該参照試料中のものと比較したときの該第1の試料中の該バイオマーカーレベルの変化が、抗腫瘍剤としての該化合物の効力を示し、
該バイオマーカーがZFP91である、前記方法。 - 前記バイオマーカーのレベルが、該バイオマーカーのRNA又はDNAレベルを決定することにより測定される、請求項1記載の方法。
- 前記バイオマーカーのレベルが、該バイオマーカーのmRNAレベルを決定することにより測定される、請求項2記載の方法。
- 前記バイオマーカーのレベルが、該バイオマーカーのcDNAレベルを決定することにより測定される、請求項2記載の方法。
- 前記バイオマーカーのレベルが、該バイオマーカーのタンパク質レベルを決定することにより測定される、請求項1記載の方法。
- 前記第1の試料が、腫瘍生検材料、節生検材料、又は骨髄、脾臓、肝臓、脳、もしくは乳房由来の生検材料から得られる、請求項1〜5のいずれか一項記載の方法。
- 前記癌が、びまん性大細胞型B細胞リンパ腫(DLBCL)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、多発性骨髄腫(MM)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、骨髄異形成症候群(MDS)である、請求項1〜6のいずれか一項記載の方法。
- 前記MDSが、染色体5qの欠失(del(5q))を有するMDSである、請求項9記載の方法。
- 前記癌が、急性骨髄性白血病(AML)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、マントル細胞リンパ腫(MCL)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、濾胞性リンパ腫(FL)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、急性骨髄芽球性白血病(AML)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、慢性リンパ球性白血病(CLL)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、非ホジキンリンパ腫(NHL)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、有毛細胞白血病である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、慢性骨髄性白血病(CML)である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、AIDS関連カポジ肉腫である、請求項1〜6のいずれか一項記載の方法。
- 前記癌が、悪性黒色腫である、請求項1〜6のいずれか一項記載の方法。
- 前記化合物が、セレブロン結合化合物である、請求項1〜20のいずれか一項記載の方法。
- 前記化合物が、レナリドマイド、ポマリドマイド、サリドマイド、3-(5-アミノ-2-メチル-4-オキソ-4H-キナゾリン-3-イル)-ピペリジン-2,6-ジオン(化合物A)、又は3-(4-((4-(モルホリノメチル)ベンジル)オキシ)-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン(化合物B)、又はその医薬として許容し得る塩、溶媒和物、水和物、共結晶、包摂化合物、もしくは多形である、請求項21記載の方法。
- 前記化合物が、レナリドマイド、又はその医薬として許容し得る塩、溶媒和物、水和物、共結晶、包摂化合物、もしくは多形である、請求項22記載の方法。
- 前記化合物が、ポマリドマイド、又はその医薬として許容し得る塩、溶媒和物、水和物、共結晶、包摂化合物、もしくは多形である、請求項22記載の方法。
- 前記化合物が、サリドマイド、又はその医薬として許容し得る塩、溶媒和物、水和物、共結晶、包摂化合物、もしくは多形である、請求項22記載の方法。
- 前記化合物が、化合物A、又はその医薬として許容し得る塩、溶媒和物、水和物、共結晶、包摂化合物、もしくは多形である、請求項22記載の方法。
- 前記化合物が、化合物B、又はその医薬として許容し得る塩、溶媒和物、水和物、共結晶、包摂化合物、もしくは多形である、請求項22記載の方法。
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913003P | 2013-12-06 | 2013-12-06 | |
US61/913,003 | 2013-12-06 | ||
US201461947963P | 2014-03-04 | 2014-03-04 | |
US61/947,963 | 2014-03-04 | ||
US201461990621P | 2014-05-08 | 2014-05-08 | |
US61/990,621 | 2014-05-08 | ||
US201462061050P | 2014-10-07 | 2014-10-07 | |
US62/061,050 | 2014-10-07 | ||
US201462064413P | 2014-10-15 | 2014-10-15 | |
US62/064,413 | 2014-10-15 | ||
US201462077835P | 2014-11-10 | 2014-11-10 | |
US62/077,835 | 2014-11-10 | ||
US201462087111P | 2014-12-03 | 2014-12-03 | |
US62/087,111 | 2014-12-03 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016536629A Division JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型b細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019216716A JP2019216716A (ja) | 2019-12-26 |
JP2019216716A5 true JP2019216716A5 (ja) | 2020-02-13 |
JP7142612B2 JP7142612B2 (ja) | 2022-09-27 |
Family
ID=53274285
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016536629A Active JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型b細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
JP2019120643A Active JP7142612B2 (ja) | 2013-12-06 | 2019-06-28 | びまん性大細胞型b細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016536629A Active JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型b細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20160313300A1 (ja) |
EP (1) | EP3077548B1 (ja) |
JP (2) | JP6573611B2 (ja) |
KR (1) | KR102299801B1 (ja) |
AU (1) | AU2014360328B2 (ja) |
BR (1) | BR112016012795A2 (ja) |
CA (2) | CA2932120C (ja) |
EA (1) | EA201691144A1 (ja) |
ES (1) | ES2903155T3 (ja) |
IL (2) | IL278381B2 (ja) |
MX (1) | MX2016007239A (ja) |
PH (1) | PH12016501041A1 (ja) |
WO (1) | WO2015085172A2 (ja) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2420497T3 (en) | 2006-09-26 | 2016-03-07 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
RS58523B1 (sr) | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
TWI601722B (zh) | 2011-03-11 | 2017-10-11 | 西建公司 | 3-(5-胺基-2-甲基-4-氧基-4h-喹唑啉-3-基)-六氫吡啶-2,6-二酮之固體型式及其醫藥組合物及用途 |
ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
JP6657105B2 (ja) | 2013-11-06 | 2020-03-04 | アメリカ合衆国 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
BR122023024814A2 (pt) | 2015-03-31 | 2024-02-20 | Syros Pharmaceuticals, Inc. | Método ex vivo de previsão da eficácia de tamibaroteno, ou um sal farmaceuticamente aceitável do mesmo |
EP3304076A4 (en) | 2015-06-02 | 2018-12-19 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
US20170038387A1 (en) * | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
WO2017027672A1 (en) * | 2015-08-12 | 2017-02-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
US10689708B2 (en) * | 2015-09-25 | 2020-06-23 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
WO2017100259A1 (en) * | 2015-12-08 | 2017-06-15 | Icahn School Of Medicine At Mount Sinai | Pretransplant prediction of post-transplant acute rejection |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
WO2017120446A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
US11311540B2 (en) | 2016-02-17 | 2022-04-26 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs |
US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
EP3452032B1 (en) * | 2016-04-08 | 2024-09-04 | Syros Pharmaceuticals, Inc. | Rara agonists for the treatment of aml and mds |
JP7075896B2 (ja) | 2016-04-20 | 2022-05-26 | アメリカ合衆国 | マントル細胞リンパ腫の評価及びそれに関連する方法 |
SG10201607303YA (en) * | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
JP7227131B2 (ja) | 2016-12-03 | 2023-02-21 | ジュノー セラピューティクス インコーポレイテッド | Car-t細胞の投薬を決定するための方法 |
CA3045508A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
WO2018144445A1 (en) * | 2017-01-31 | 2018-08-09 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
WO2018165482A1 (en) * | 2017-03-10 | 2018-09-13 | Memorial Sloan Kettering Cancer Center | Methods for treatment or prevention of leukemia |
EP4327878A3 (en) | 2017-05-01 | 2024-05-01 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
BR112019025403A2 (pt) | 2017-06-02 | 2020-08-18 | Juno Therapeutics Inc | artigos de fabricação e métodos para tratamento usando terapia celular adotiva |
JP2020526194A (ja) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
WO2019079360A1 (en) * | 2017-10-16 | 2019-04-25 | Massachusetts Institute Of Technology | ATLAS OF HEALTHY AND ILLUMINATED TISSUE CELLS |
US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
WO2019109053A1 (en) | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
CN110448548B (zh) * | 2018-05-08 | 2023-05-05 | 四川大学华西医院 | Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途 |
BR112020023756A2 (pt) * | 2018-05-23 | 2021-02-09 | Celgene Corporation | tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila |
EP3876958A1 (en) | 2018-11-08 | 2021-09-15 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
US20220008465A1 (en) | 2018-11-16 | 2022-01-13 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
SG11202105502RA (en) | 2018-11-30 | 2021-06-29 | Juno Therapeutics Inc | Methods for treatment using adoptive cell therapy |
CN109583222A (zh) * | 2018-12-07 | 2019-04-05 | 浪潮(北京)电子信息产业有限公司 | 分布式文件系统元数据服务器回收客户端权限方法及装置 |
PE20212198A1 (es) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) |
SG11202109024YA (en) | 2019-04-12 | 2021-09-29 | C4 Therapeutics Inc | Tricyclic degraders of ikaros and aiolos |
WO2020231937A1 (en) * | 2019-05-10 | 2020-11-19 | University Of Massachusetts | Irf2 as a prognostic biomarker and target for augmenting immunotherapy |
WO2021016079A2 (en) * | 2019-07-19 | 2021-01-28 | Pascal Biosciences (Us), Inc. | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |
WO2021102420A1 (en) * | 2019-11-22 | 2021-05-27 | The Regents Of The University Of California | Interferon signaling as a cancer biomarker |
CN111187755B (zh) * | 2020-02-20 | 2021-10-22 | 中国人民解放军军事科学院军事医学研究院 | 抗tpd52单克隆抗体杂交瘤细胞株及其单克隆抗体与应用 |
KR20230128096A (ko) * | 2020-12-31 | 2023-09-01 | 엘레파스 바이오사이언스 코퍼레이션 | 조직에 대한 약물 또는 기타 제제의 효과를 결정하기위한 생체외 시스템 및 방법 |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
MX2023009090A (es) * | 2021-02-03 | 2023-10-18 | Curis Inc | Biomarcadores para la terapia con fimepinostat. |
KR102629955B1 (ko) * | 2021-02-19 | 2024-01-25 | 가톨릭대학교 산학협력단 | Ewsr1의 발현 또는 활성 촉진제를 포함하는 비알콜성 지방간염 예방 또는 치료용 약학적 조성물 |
CN113025720B (zh) * | 2021-04-28 | 2022-12-27 | 深圳市人民医院 | 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用 |
WO2023039405A1 (en) * | 2021-09-08 | 2023-03-16 | The Curators Of The University Of Missouri | Methods of using usp15 inhibitors |
WO2023222565A1 (en) * | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
ATE205542T1 (de) | 1992-03-04 | 2001-09-15 | Univ California | Vergleichende genomhybridisierung |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
WO2007086915A2 (en) | 2005-05-12 | 2007-08-02 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
ES2426350T3 (es) | 2006-08-30 | 2013-10-22 | Celgene Corporation | Compuestos de isoindolina sustituidos en 5 |
KR20090071603A (ko) * | 2006-09-19 | 2009-07-01 | 노파르티스 아게 | Raf 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커 |
JP2011505808A (ja) * | 2007-12-07 | 2011-03-03 | セルジーン コーポレイション | 非ホジキンリンパ腫の治療の間における、免疫調節化合物に対する細胞の感受性を予測するためのバイオマーカー |
WO2009149319A2 (en) * | 2008-06-05 | 2009-12-10 | Wyeth | Gene expression profiles associated with asthma exacerbation attacks |
WO2010017515A2 (en) | 2008-08-08 | 2010-02-11 | Integrated Diagnostics Inc. | Breast cancer specific markers and methods of use |
NZ592425A (en) | 2008-10-29 | 2013-04-26 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer |
AU2010236606A1 (en) * | 2009-04-14 | 2011-11-03 | Merck Sharp & Dohme Corp. | Interferon-alfa sensitivity biomarkers |
CN102448472A (zh) | 2009-05-25 | 2012-05-09 | 国立大学法人东京工业大学 | 包含与中枢神经细胞的增殖和分化相关的核因子的药物组合物 |
CN102576023B (zh) * | 2009-10-20 | 2014-07-09 | 国立大学法人东京工业大学 | 利用沙利度胺靶向因子的筛选方法 |
RS58523B1 (sr) | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
WO2011133129A1 (en) | 2010-04-21 | 2011-10-27 | Puritan Medical Products Company, Llc | Collection device and material |
US20110301102A1 (en) * | 2010-06-07 | 2011-12-08 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
CN103561744A (zh) * | 2011-03-11 | 2014-02-05 | 细胞基因公司 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮在治疗免疫相关性和炎症性疾病中的用途 |
EP3266452B1 (en) * | 2011-03-11 | 2019-07-03 | Mayo Foundation for Medical Education and Research | Means to treat myelomas which are resistant to thalidomide, lenalidomide or pomalidomide |
US9365640B2 (en) | 2011-04-29 | 2016-06-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
EP2944961A1 (en) * | 2011-05-06 | 2015-11-18 | XenTech | Markers for cancer prognosis and therapy and methods of use |
US8901110B2 (en) * | 2012-01-13 | 2014-12-02 | Celgene Corporation | Use of biomarkers in methods for the treatment of hepatocellular carcinoma |
JP6318152B2 (ja) | 2012-06-29 | 2018-04-25 | セルジーン コーポレイション | セレブロン関連タンパク質を利用して薬物効能を決定する方法 |
NZ628078A (en) | 2012-08-09 | 2017-01-27 | Celgene Corp | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
KR102382576B1 (ko) | 2013-04-17 | 2022-04-08 | 시그날 파마소티칼 엘엘씨 | 암 치료를 위한 TOR 키나제 억제제 및 IMiD 화합물을 포함하는 조합요법 |
US20160282354A1 (en) * | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
MX2016007179A (es) | 2013-12-06 | 2016-09-08 | Celgene Corp | Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. |
EP3207151A4 (en) | 2014-10-13 | 2018-07-04 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
EP3304076A4 (en) | 2015-06-02 | 2018-12-19 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
WO2017027672A1 (en) | 2015-08-12 | 2017-02-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
US10689708B2 (en) | 2015-09-25 | 2020-06-23 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
WO2017120446A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
-
2014
- 2014-12-05 WO PCT/US2014/068795 patent/WO2015085172A2/en active Application Filing
- 2014-12-05 CA CA2932120A patent/CA2932120C/en active Active
- 2014-12-05 IL IL278381A patent/IL278381B2/en unknown
- 2014-12-05 EA EA201691144A patent/EA201691144A1/ru unknown
- 2014-12-05 JP JP2016536629A patent/JP6573611B2/ja active Active
- 2014-12-05 MX MX2016007239A patent/MX2016007239A/es unknown
- 2014-12-05 BR BR112016012795A patent/BR112016012795A2/pt not_active Application Discontinuation
- 2014-12-05 US US15/101,869 patent/US20160313300A1/en not_active Abandoned
- 2014-12-05 EP EP14868331.1A patent/EP3077548B1/en active Active
- 2014-12-05 KR KR1020167016778A patent/KR102299801B1/ko active IP Right Grant
- 2014-12-05 ES ES14868331T patent/ES2903155T3/es active Active
- 2014-12-05 AU AU2014360328A patent/AU2014360328B2/en active Active
- 2014-12-05 CA CA3206268A patent/CA3206268A1/en active Pending
-
2016
- 2016-06-01 IL IL245981A patent/IL245981B/en active IP Right Grant
- 2016-06-01 PH PH12016501041A patent/PH12016501041A1/en unknown
-
2018
- 2018-04-05 US US15/946,618 patent/US10996215B2/en active Active
-
2019
- 2019-06-28 JP JP2019120643A patent/JP7142612B2/ja active Active
-
2021
- 2021-04-01 US US17/220,377 patent/US20220003749A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019216716A5 (ja) | ||
IL278381B2 (en) | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer | |
Waarts et al. | Targeting mutations in cancer | |
JP2018535951A5 (ja) | ||
Shain et al. | The tumor microenvironment shapes hallmarks of mature B-cell malignancies | |
van Weverwijk et al. | Mechanisms driving the immunoregulatory function of cancer cells | |
Abou Zahr et al. | Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies | |
Gainor et al. | Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer | |
Rescigno et al. | Characterizing CDK12-mutated prostate cancers | |
Jiang et al. | Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy | |
Nardi et al. | Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment | |
Swanton | Intratumor heterogeneity: evolution through space and time | |
Garralda et al. | Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment | |
Sanchez-Tillo et al. | The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma | |
Rasheed et al. | Concise review: emerging concepts in clinical targeting of cancer stem cells | |
RU2018107668A (ru) | Пиразолпиримидиновое производное и его применение | |
Evans et al. | A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors | |
JP2018512413A5 (ja) | ||
RU2017103757A (ru) | Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы | |
Waller | Imatinib mesylate | |
Wang et al. | Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers | |
JP2017501400A5 (ja) | ||
JP2018536636A5 (ja) | ||
Lebovitz et al. | Here, there be dragons: charting autophagy-related alterations in human tumors | |
Krause et al. | Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia |